In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...
How Can Biomarkers Help Individualize Treatment of Diffuse Large B-cell Lymphoma? Using Biomarkers to Diagnose Diffuse Large B-cell Lymphoma ...
Jeremy S Abramson and colleagues reported that glofitamab plus gemcitabine and oxaliplatin (GemOx) significantly improved overall survival (OS) in transplant-ineligible patients with relapsed or ...
CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma. Results ...
Diffuse large B cell lymphoma (DLBCL) is a prevalent subtype of non-Hodgkins lymphoma and can occasionally present as a rare and aggressive testicular variant. This case presents a middle-aged male ...
- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent need ...
In this video, Tycel Phillips, MD, discusses initial results of a phase 1b clinical trial focused on treating diffuse large B ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback